The first case of Pulmonary Arterial Hypertension was reported in 1891, when the German doctor E. Romberg published a description of a patient whose autopsy revealed pulmonary artery thickening but no heart or lung disease that could have caused the condition. Dr. D.T. Dresdale reported three cases in the United States in 1951, and the illness was originally known as primary pulmonary hypertension, which is no longer used but broadly refers to a type of pulmonary arterial hypertension (PAH). Diet drugs such as Fen-Phen, Pondimin, and Redux have been linked to PAH. These drugs were removed from the market in 1997, but cases involving drugs and toxins, such as methamphetamines, continue to emerge.
Pulmonary Arterial Hypertension is also associated with a number of other medical diseases such as cirrhosis, congenital heart disease and connective tissue diseases like scleroderma. About 30% of patients with PAH have an associated connective tissue disease.
Explore more- https://coherentmarketinsightsus.blogspot.com/2022/08/symptoms-of-pulmonary-arterial.html
